AI Engines For more Details: Perplexity Kagi Labs You
Schizophrenia: Sertindole is indicated for the treatment of schizophrenia, a chronic mental disorder characterized by disturbances in thinking, perception, emotions, and behavior. It helps alleviate symptoms such as hallucinations (perceiving things that are not present), delusions (false beliefs), disorganized thinking, social withdrawal, lack of motivation, and emotional blunting.
Positive Symptoms: Sertindole effectively targets positive symptoms of schizophrenia, which include hallucinations, delusions, disorganized speech, and disorganized behavior. These symptoms often respond well to antipsychotic medications like sertindole.
Negative Symptoms: While antipsychotics like sertindole primarily target positive symptoms, they may also have some effect on negative symptoms of schizophrenia, such as social withdrawal, apathy, lack of motivation, and blunted affect.
Cognitive Symptoms: Some research suggests that certain antipsychotic medications, including sertindole, may have modest effects on cognitive symptoms of schizophrenia, such as impaired memory, attention, and executive function. However, the extent of improvement in cognitive function with sertindole may vary among individuals.
Duration of Treatment: Sertindole is typically used as a long-term treatment for schizophrenia to maintain symptom control and prevent relapse. It is often prescribed in conjunction with psychosocial interventions, such as therapy and support services, to optimize treatment outcomes.
Side Effects: Like other antipsychotic medications, sertindole may cause side effects, including weight gain, sedation, dizziness, dry mouth, constipation, blurred vision, and sexual dysfunction. It may also increase the risk of metabolic abnormalities, such as diabetes and dyslipidemia, and cardiac effects, including prolongation of the QT interval.
Monitoring: Patients prescribed sertindole should undergo regular monitoring, including physical examinations, weight checks, blood tests (e.g., glucose and lipid levels), and electrocardiograms (ECGs) to assess cardiac function and monitor for potential adverse effects.
Black Box Warning: Sertindole carries a black box warning regarding the risk of sudden cardiac death due to QT interval prolongation. Therefore, it should be used with caution in patients with preexisting cardiac conditions or those taking other medications that may prolong the QT interval.
Drug Interactions: Sertindole may interact with other medications, including certain antibiotics, antifungal agents, antidepressants, antipsychotics, and medications that affect cardiac conduction. Healthcare providers should carefully evaluate potential drug interactions before prescribing sertindole.
Tapering Off: Discontinuation of sertindole should be done gradually under medical supervision to minimize the risk of withdrawal symptoms and symptom recurrence.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | 0.3 | |
| ADHD | 2.4 | 2.4 | |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 1.6 | 0.6 | 1.67 |
| Allergies | 3.2 | 1.8 | 0.78 |
| Allergy to milk products | 0.3 | 0.7 | -1.33 |
| Alopecia (Hair Loss) | 1.2 | 1.2 | |
| Alzheimer's disease | 4.2 | 4.4 | -0.05 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 1.8 | |
| Ankylosing spondylitis | 2.6 | 0.9 | 1.89 |
| Anorexia Nervosa | 0.7 | 2.3 | -2.29 |
| Antiphospholipid syndrome (APS) | 1.5 | 0.3 | 4 |
| Asthma | 3.2 | 1.1 | 1.91 |
| Atherosclerosis | 1.2 | 2 | -0.67 |
| Atrial fibrillation | 2.8 | 2.2 | 0.27 |
| Autism | 4.9 | 6.6 | -0.35 |
| Autoimmune Disease | 0.3 | 0.5 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.2 | 1.2 | |
| Bipolar Disorder | 1 | 0.5 | 1 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.3 | 0.3 | |
| Carcinoma | 2.8 | 1.3 | 1.15 |
| Celiac Disease | 2.4 | 1.9 | 0.26 |
| Cerebral Palsy | 0.6 | 0.8 | -0.33 |
| Chronic Fatigue Syndrome | 2.1 | 3.9 | -0.86 |
| Chronic Kidney Disease | 1.3 | 1.7 | -0.31 |
| Chronic Lyme | 0 | 0.8 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 1.4 | -0.17 |
| Chronic Urticaria (Hives) | 0.3 | 1.2 | -3 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.8 | -0.14 |
| Cognitive Function | 2.1 | 0.8 | 1.63 |
| Colorectal Cancer | 5.2 | 1.4 | 2.71 |
| Constipation | 1.2 | 0.5 | 1.4 |
| Coronary artery disease | 0.6 | 2 | -2.33 |
| COVID-19 | 3.7 | 6.6 | -0.78 |
| Crohn's Disease | 5.7 | 4.2 | 0.36 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 1.7 | 1.1 | 0.55 |
| Denture Wearers Oral Shifts | 1.2 | 1.2 | |
| Depression | 6.4 | 5.1 | 0.25 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.6 | 1.8 | -2 |
| Endometriosis | 1.6 | 0.8 | 1 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 1.5 | 1.3 | 0.15 |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 2.2 | 2 | 0.1 |
| Functional constipation / chronic idiopathic constipation | 3.1 | 2.5 | 0.24 |
| gallstone disease (gsd) | 1.6 | 0.8 | 1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.1 | 0.6 | 2.5 |
| Generalized anxiety disorder | 0.9 | 1.1 | -0.22 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.2 | 1.2 | |
| Graves' disease | 0.7 | 1.7 | -1.43 |
| Gulf War Syndrome | 0.3 | 1.2 | -3 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 2.3 | 0.9 | 1.56 |
| Heart Failure | 2.4 | 1.7 | 0.41 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 1.4 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hyperglycemia | 0.4 | 0.7 | -0.75 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2.5 | 3.8 | -0.52 |
| Hypoxia | 1.3 | 0.6 | 1.17 |
| IgA nephropathy (IgAN) | 1.3 | 2.9 | -1.23 |
| Inflammatory Bowel Disease | 4.7 | 5.3 | -0.13 |
| Insomnia | 1.5 | 1.7 | -0.13 |
| Intelligence | 0.9 | 0.6 | 0.5 |
| Intracranial aneurysms | 1 | 1 | |
| Irritable Bowel Syndrome | 3.5 | 3 | 0.17 |
| ischemic stroke | 1 | 1.1 | -0.1 |
| Liver Cirrhosis | 4.5 | 2.3 | 0.96 |
| Long COVID | 3.7 | 4.2 | -0.14 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.3 | 0.6 | -1 |
| Mast Cell Issues / mastitis | 0.9 | 0.9 | |
| ME/CFS with IBS | 1 | 0.3 | 2.33 |
| ME/CFS without IBS | 0.3 | 1.5 | -4 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 3.6 | 5.1 | -0.42 |
| Mood Disorders | 5.2 | 3.3 | 0.58 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 3.1 | 4.6 | -0.48 |
| Multiple system atrophy (MSA) | 0.9 | 0.9 | |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 2.2 | -2.2 | |
| Neuropathy (all types) | 0.3 | 1 | -2.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.9 | 1.7 | 0.71 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 4.8 | 4.3 | 0.12 |
| obsessive-compulsive disorder | 3.1 | 2 | 0.55 |
| Osteoarthritis | 1.2 | 0.6 | 1 |
| Osteoporosis | 1.4 | 1.2 | 0.17 |
| pancreatic cancer | 1.2 | 0.6 | 1 |
| Parkinson's Disease | 2.8 | 5.3 | -0.89 |
| Polycystic ovary syndrome | 4.2 | 1.4 | 2 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.9 | 1.2 | -0.33 |
| Primary sclerosing cholangitis | 1.6 | 1 | 0.6 |
| Psoriasis | 0.9 | 3.1 | -2.44 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.9 | 2.9 | 0.34 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 2.5 | 1.6 | 0.56 |
| scoliosis | 0.9 | -0.9 | |
| Sjögren syndrome | 1.3 | 2.2 | -0.69 |
| Sleep Apnea | 1.2 | 0.8 | 0.5 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 0.9 | |
| Stress / posttraumatic stress disorder | 2.1 | 1.3 | 0.62 |
| Systemic Lupus Erythematosus | 2.2 | 1.2 | 0.83 |
| Tic Disorder | 0.9 | 1.2 | -0.33 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3.2 | 2 | 0.6 |
| Type 2 Diabetes | 5.1 | 4.8 | 0.06 |
| Ulcerative colitis | 3.7 | 5.2 | -0.41 |
| Unhealthy Ageing | 4.2 | 1.6 | 1.63 |
| Vitiligo | 1.9 | 0.4 | 3.75 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
